Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
- 1 February 1999
- journal article
- Published by Elsevier BV in Urology
- Vol. 53 (2), 260-266
- https://doi.org/10.1016/s0090-4295(98)00539-1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- LONG-TERM RESULTS OF RADIATION THERAPY FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMYJournal of Urology, 1998
- Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccineProceedings of the National Academy of Sciences, 1997
- Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigenThe Prostate, 1996
- Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot studyUrology, 1996
- A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primateInternational Journal of Cancer, 1995
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated BoostingThe Journal of Infectious Diseases, 1994
- Vaccinia Virus: A Tool for Research and Vaccine DevelopmentScience, 1991
- Adjuvant immunotherapy (BCG) in Stage D prostate cancerAmerican Journal of Clinical Oncology, 1982
- Abnormalities of Cell-Mediated Immunocompetence in Genitourinary CancerJournal of Urology, 1974